financetom
Business
financetom
/
Business
/
Coinbase Global Insider Sold Shares Worth $824,765, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Coinbase Global Insider Sold Shares Worth $824,765, According to a Recent SEC Filing
May 22, 2024 1:36 PM

04:23 PM EDT, 05/22/2024 (MT Newswires) -- Alesia J Haas, Chief Financial Officer, on May 20, 2024, sold 3,880 shares in Coinbase Global ( COIN ) for $824,765. Following the Form 4 filing with the SEC, Haas has control over a total of 212,649 shares of the company, with 191,753 shares held directly and 20,896 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1679788/000167978824000098/xslF345X03/wk-form4_1716408648.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Pixie Dust Technologies (PXDT) Stock Is Down 30%
Why Pixie Dust Technologies (PXDT) Stock Is Down 30%
Oct 25, 2024
Pixie Dust Technologies Inc ( PXDT ) shares are trading lower by 29.6% to $1.14 during Thursday’s session after the company’s board has resolved to voluntarily delist its ADRs from the NASDAQ Capital Market and will apply for deregistration with the SEC. What Else: PXDT says the decision, driven by the high costs of maintaining the NASDAQ listing and ongoing...
Ingram Micro Holding Shares Rise in NYSE Debut
Ingram Micro Holding Shares Rise in NYSE Debut
Oct 25, 2024
12:39 PM EDT, 10/24/2024 (MT Newswires) -- Ingram Micro Holding ( INGM ) shares rose 12% in recent Thursday trading in their New York Stock Exchange debut. The stock with the ticker INGM earlier climbed as high as $25.69 before trading at $24.56 at midday. Intraday volume topped 3.54 million shares The initial public offering of 18.6 million shares was...
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options
Oct 25, 2024
On Thursday, Marinus Pharmaceuticals, Inc. ( MRNS ) stock plunged after the company revealed disappointing data from the Phase 3 TrustTSC trial of oral ganaxolone for seizures associated with tuberous sclerosis complex (TSC) in children and adults. TSC is a rare genetic condition that mainly causes non-cancerous (benign) tumors to develop in different body parts. Also Read: Marinus Pharmaceuticals Shares Mixed Results...
Garrett Motion Q3: Sales Plummet 14% Amid Weak Vehicle Demand, Cuts FY24 Topline Forecast
Garrett Motion Q3: Sales Plummet 14% Amid Weak Vehicle Demand, Cuts FY24 Topline Forecast
Oct 25, 2024
Garrett Motion Inc. ( GTX ) shares are trading lower after the company reported worse-than-expected third-quarter results and reduced its FY24 net sales guidance. Sales declined 14% (reported and constant currency basis) year-over-year to $826 million, missing the consensus of $851 million. The decline was primarily due to weaker light vehicle sales caused by industry softness in Europe and China, competitive pressures on...
Copyright 2023-2025 - www.financetom.com All Rights Reserved